Comments on Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin-naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting

Craig J. Currie Honorary Senior Research Fellow, Diabetes, Endocrinology and Metabolism, School of Medicine, Cardiff University, UK. email: [email protected]

Phil McEwan Lecturer in Computational Statistics, School of Mathematics, Cardiff University, UK

Chris Poole Senior Research Pharmacist, Cardiff, UK

William J. Valentine CORE – Center for Outcomes Research, Bündtenmattstrasse 40, 4102 Binningen, Switzerland. email: [email protected]@thecenter.ch

Andrew J. Palmer CORE – Center for Outcomes Research, Bündtenmattstrasse 40, 4102 Binningen, Switzerland. email: [email protected]@thecenter.ch

Morten Lammert Novo Nordisk A/S, Bagsvaerd, Denmark

Lars Nicklasson Novo Nordisk Inc., Princeton, NJ, USA

Volker Foos CORE – Center for Outcomes Research, Bündtenmattstrasse 40, 4102 Binningen, Switzerland. email: [email protected]@thecenter.ch

Stéphane Roze CORE – Center for Outcomes Research, Bündtenmattstrasse 40, 4102 Binningen, Switzerland. email: [email protected]@thecenter.ch

show all

Click to increase image sizeClick to decrease image size

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Comments on Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin-naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting

Information for

Open access

Opportunities

Help and information

Comments on Long-term clinical and cost outcomes of treatment with biphasic insulin aspart 30/70 versus insulin glargine in insulin-naïve type 2 diabetes patients: cost-effectiveness analysis in the UK setting

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature